Drug intelligence / Profile preview

decorin

Development stage
Phase 2
Lead developer
Phoenicis Therapeutics
Modality
Recombinant Proteins and Enzymes
Administration
Intravenous, Subcutaneous, Intratumoral, Topical, Ophthalmic, Inhalation, Intramuscular, Intraperitoneal
01

Overview

Decorin is a small leucine-rich proteoglycan (SLRP) and an extracellular matrix protein encoded by the DCN gene. It is primarily known for its role in organizing collagen fibrils and maintaining connective tissue structure. Decorin binds to type I collagen and regulates fibrillogenesis as well as matrix assembly[3][6]. Beyond structural functions, decorin acts as a multifunctional signaling molecule that interacts with various receptor tyrosine kinases (RTKs), including EGFR (epidermal growth factor receptor), HER2, Met (hepatocyte growth factor receptor), VEGFR2 (vascular endothelial growth factor receptor 2), TLRs (Toll-like receptors), and IGFR[1][5][7]. Through these interactions it can inhibit tumor cell proliferation and metastasis by suppressing downstream signaling pathways involved in cell cycle progression and angiogenesis; it also induces autophagy/mitophagy in cancer cells[1][5]. Decorin antagonizes transforming growth factor-beta (TGF-β) activity by direct binding—attenuating fibrosis—and modulates immune responses via engagement of pattern recognition receptors such as TLR2/4 on macrophages[1][2]. It has been studied for potential therapeutic applications in cancer treatment due to its oncosuppressive properties; other roles include regulation of inflammation, wound healing, fibrosis inhibition, myokine activity promoting muscle hypertrophy via myostatin binding, modulation of angiogenesis through VEGFR2 inhibition/autophagic induction in endothelial cells[3][4].

Other names
decorin proteoglycandermatan sulphate proteoglycans 2proteoglycan II
02

Targets

VEGFR2 (Vascular endothelial growth factor receptor 2)MET (Mesenchymal-epithelial transition factor receptor)TGFB (GARP–latent transforming growth factor beta 1 complex)TLR4 (Toll-like receptor 4)EGFR T790M (Epidermal growth factor receptor T790M mutant)

Beyond the preview

Go deeper on decorin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on decorin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call